What is MCV4 Menactra vaccine?

What is MCV4 Menactra vaccine?

Meningococcal conjugate vaccine (MCV4) is the preferred vaccine for those aged 2 to 55. Meningococcal polysaccharide vaccine (MPSV4) may be used if MCV4 is not available; it is also licensed for people older than 55. Both vaccines work well, and protect approximately 90 percent of those who get vaccinated.

What is the menactra Menveo vaccine?

Vaccines can help prevent meningococcal disease, which is any type of illness caused by Neisseria meningitidis bacteria. There are 2 types of meningococcal vaccines available in the United States: Meningococcal conjugate or MenACWY vaccines (Menactra®, Menveo®, and MenQuadfi®)

What is the MCV4 #2 vaccine?

MCV4 or meningococcal conjugate vaccine, is a two-dose booster shot. It helps protect against four types of the bacteria that cause meningococcal disease (serogroups A, C, W and Y). While most people who get the vaccine do not have any serious side effects it is always a possibility.

What does menveo cover?

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons aged 2 months through 55 years. MENVEO does not prevent N. meningitidis serogroup B infections.

Is menveo a MCV4?

One type of MCV4, Menveo, is licensed for use in people ages 2 to 55. Another version, Menactra, is approved for those 9 months to 55 years old. MPSV4 is the only vaccine licensed for use in people over 55 as well as people 2 to 55. Both vaccines protect against four types of meningococcal disease.

How many doses of Menveo are needed?

Administer MenACWY vaccines (Menactra®, Menveo®, or MenQuadfi®) to adolescents as 1 primary dose at 11 to 12 years of age. Administer 1 booster dose at 16 years of age. The minimum interval between doses is at least 8 weeks. The number of doses and schedule for patients under 2 years of age varies by vaccine product.

How is Menveo supplied?

Each dose of MENVEO should be administered as a single 0.5-mL intramuscular injection, preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle (upper arm) in toddlers, adolescents, and adults. Do not administer MENVEO intravenously, subcutaneously, or intradermally.

What is meningococcal conjugate?

Meningococcal conjugate (MenACWY) vaccine protects against four types (serogroups A, C, W, and Y) of Neisseria meningitidis bacteria. Serogroup B meningococcal (MenB) vaccine protects against one type (serogroup B) of Neisseria meningitidis bacteria.